Novo Nordisk A/S: Nutrition Disorders trials

The registry lists 37 Nutrition Disorders studies with Novo Nordisk A/S as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 22Phase 2 2Phase 3 10No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityCompletedNCT03548987Phase 3Results posted
• STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityCompletedNCT03548935Phase 3Results posted
• Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist SettingCompletedNCT02963935Phase 3Results posted
• Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal InsulinCompletedNCT02963922Phase 3Results posted
• Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With ObesityCompletedNCT02918279Phase 3Results posted
• Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeCompletedNCT02527200Phase 3Results posted
• Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusCompletedNCT02453711Phase 2Results posted
• Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep ApnoeaCompletedNCT01557166Phase 3Results posted
• Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - DiabetesCompletedNCT01272232Phase 3Results posted
• Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesCompletedNCT01272219Phase 3Results posted
• Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - MaintenanceCompletedNCT00781937Phase 3Results posted
• The Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesCompletedNCT00422058Phase 2Results posted
• Research Study of a New Medicine (NNC9204-1706) in People With Overweight or ObesityCompletedNCT03661879Phase 1
• A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or ObeseCompletedNCT03574584Phase 1
• A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or ObesityCompletedNCT03479892Phase 1
• Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or ObesityCompletedNCT03308721Phase 1
• Awareness, Care and Treatment in Obesity ManagementCompletedNCT03235102
• Awareness, Care & Treatment in Obesity Management (ACTION) StudyCompletedNCT03223493
• Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With ObesityCompletedNCT03095807Phase 1
• First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or ObesityCompletedNCT03015207Phase 1
• In-market Utilisation of Liraglutide Used for Weight Management in EuropeCompletedNCT02967757
• Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or OverweightCompletedNCT02958085Phase 1
• A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.CompletedNCT02941042Phase 1
• Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With ObesityCompletedNCT02870231Phase 1
• A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With ObesityCompletedNCT02835235Phase 1
• A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.CompletedNCT02717858Phase 1
• A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 YearsCompletedNCT02696148Phase 1
• A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy SubjectsCompletedNCT02568306Phase 1
• Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsCompletedNCT02300844Phase 1
• Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male SubjectsCompletedNCT02235961Phase 1
• Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectorsCompletedNCT02207348Phase 1
• Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With PlaceboCompletedNCT02079870Phase 1
• A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 YearsCompletedNCT01789086Phase 1
• A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy VolunteersTerminatedNCT01044108Phase 1
• A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese VolunteersCompletedNCT00978393Phase 1
• Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese VolunteersWithdrawnNCT00728455Phase 1
• Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female VolunteersTerminatedNCT00665665Phase 1